This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Allan J. Flach, MD; Bernard J. Dolan, OD
San Francisco, Calif

Arch Ophthalmol. 1990;108(12):1668-1669.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Amiodarone hydrochloride is a benzofurane derivative used for cardiac abnormalities. It has recently been approved by the Food and Drug Administration for use in cardiac arrythmias (Cordarone; Wyeth, Philadelphia, Pa). Eight years ago, visually insignificant anterior subcapsular (ASC) lens opacities were reported in seven of 14 patients using moderate to high doses of amiodarone who were treated at the Veterans Affairs Medical Center in San Francisco, Calif.¹ A summary of the present ocular status of these 14 patients 8 years later is provided in the Table.

The first report of lens opacities in patients receiving amiodarone describes them as anterior, subcapsular, white-yellow, loosely packed, and covering an area greater than 2 mm in a loosely distributed fashion, with clear spaces between deposits.¹ They are clearly distinguished from axial punctate opacities, which are found in the general population and are pigmented, tightly packed, and cover an . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?